In the BioHarmony Drug Report Database

"Preview" Icon

Ibuprofen lysine

Neoprofen, Pedea (ibuprofen lysine) is a small molecule pharmaceutical. Ibuprofen lysine was first approved as Neoprofen on 2004-07-28. It is used to treat ankylosing spondylitis, bursitis, dysmenorrhea, fever, and gout amongst others in the USA. It has been approved in Europe to treat patent ductus arteriosus. The pharmaceutical is active against prostaglandin G/H synthase 1 and prostaglandin G/H synthase 2. In addition, it is known to target acid-sensing ion channel 1, sodium-coupled monocarboxylate transporter 1, and peroxisome proliferator-activated receptor gamma. Neoprofen’s patent is valid until 2032-03-02 (FDA).

 

Trade Name

 

Pedea
 

Common Name

 

ibuprofen lysine
 

ChEMBL ID

 

CHEMBL1201141
 

Indication

 

ankylosing spondylitis, bursitis, dysmenorrhea, fever, gout, inflammation, juvenile arthritis, menorrhagia, osteoarthritis, patent ductus arteriosus, postoperative pain, premenstrual syndrome, rheumatoid arthritis
 

Drug Class

 

Anti-inflammatory/analgesic agents (ibuprofen type)

Image (chem structure or protein)

Ibuprofen lysine structure rendering